Waters Corporation WAT
433.54
3.24
0.75%
as of 25 Sep
- Market cap
- $42.3B
- P/E
- 108×
Follow WAT
Indexes
indicate stock being part of an index,
Insider Buys
alert about insiders buying in the last 12 month
Waters Corporation (WAT) P/E ratio
As of 25 September 2026, Waters Corporation (WAT) trades at a P/E ratio of 108×. Over the past ten years it has ranged from 18.3× (March 2020) to 911× (January 2018); the current reading is higher than 92% of that period. That is above the Diagnostics & Research industry median of 33.9× and above the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 35.2× | 2.10% |
| FY2024 | 34.5× | 14.25% |
| FY2023 | 30.2× | 3.21% |
| FY2022 | 29.2× | (11.56%) |
| FY2021 | 33.1× | 12.11% |
| FY2020 | 29.5× | 11.70% |
| FY2019 | 26.4× | 8.32% |
| FY2018 | 24.4× | (97.01%) |
| FY2017 | 815× | 3,766.79% |
| FY2016 | 21.1× | (10.53%) |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 93.3× | 146.86% |
| Mar 2026 | 37.8× | 7.36% |
| Dec 2025 | 35.2× | 28.10% |
| Sep 2025 | 27.5× | (12.37%) |
| 42 more quarters | Free account |
Against its own ten years
Low 18.3×
High 911×
Ten-year median
28.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NTRA Natera, Inc. compare | n/m |
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 24.8× |
| IQV IQVIA Holdings Inc. compare | 33.3× |
| MTD Mettler-Toledo International, Inc. compare | 33.9× |
| A Agilent Technologies, Inc. compare | 33.9× |
| IDXX IDEXX Laboratories, Inc. compare | 36.2× |
| ILMN Illumina, Inc. compare | 50.4× |
| WAT Waters Corporation | 108× |
| Diagnostics & Research industry median | 33.9× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on WAT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement